Factor XIII (13), Screen, Plasma
Use
Factor XIII is crucial for blood clot stability. Screening for its deficiency helps diagnose congenital or acquired conditions that might lead to severe bleeding disorders. Patients with congenital FXIII deficiency often experience bleeding, including from the umbilical stump, and are at risk for delayed bleeding after injuries. The test determines if the stability of fibrin clots is compromised due to insufficient activation or deficiency of factor XIII, which can also affect wound healing and cause recurrent spontaneous abortions in heterozygous females.
Special Instructions
This test is part of the Bleeding Diathesis Profile, Limited, Plasma. It is not orderable separately and must be performed as part of the profile to provide appropriate diagnostic context.
Limitations
Normal screening results do not exclude the possibility of a heterozygous deficiency of factor XIII. The test specifically measures the stability of fibrin clots in monocyclic acetic acid, indicating factor XIII activity only in terms of covalent cross-linking ability. It does not provide quantitative measures of other clot factors and might not detect all heterozygous carriers.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 3241-7
- 3241-7
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Container
Na Cit
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |